127 related articles for article (PubMed ID: 33577252)
1. Are Hepatitis C Positive Female Liver Transplant Recipients Still at Increased Risk for Graft Failure? Reexamining the Disparity in the Modern Era of Direct-acting Antiviral Agents.
Yoeli D; Choudhury RA; Moore HB; Sauaia A; Simpson MA; Pomfret EA; Nydam TL
Transplantation; 2022 Jan; 106(1):129-137. PubMed ID: 33577252
[TBL] [Abstract][Full Text] [Related]
2. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Liver Transpl; 2019 Apr; 25(4):598-609. PubMed ID: 30716208
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.
Camargo JF; Anjan S; Chin-Beckford N; Morris MI; Abbo LM; Simkins J; Ciancio G; Chen LJ; Burke GW; Figueiro J; Guerra G; Kupin WL; Mattiazzi A; Ortigosa-Goggins M; Ram Bhamidimarri K; Roth D
Clin Transplant; 2019 May; 33(5):e13532. PubMed ID: 30866102
[TBL] [Abstract][Full Text] [Related]
4. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
Tanaka T; Voigt MD
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
[TBL] [Abstract][Full Text] [Related]
5. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
6. Retransplantation outcomes for hepatitis C in the United States before and after direct-acting antiviral introduction.
Ivanics T; Rizzari M; Moonka D; Al-Kurd A; Delvecchio K; Kitajima T; Elsabbagh AM; Collins K; Yoshida A; Abouljoud M; Nagai S
Am J Transplant; 2021 Mar; 21(3):1100-1112. PubMed ID: 32794649
[TBL] [Abstract][Full Text] [Related]
7. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era.
Shaikh A; Goli K; Lee TH; Rich NE; Benhammou JN; Keeling S; Kim D; Ahmed A; Goss J; Rana A; Singal AG; Kanwal F; Cholankeril G
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2288-2297.e4. PubMed ID: 36521738
[TBL] [Abstract][Full Text] [Related]
8. The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.
Axelrod DA; Schnitzler MA; Alhamad T; Gordon F; Bloom RD; Hess GP; Xiao H; Nazzal M; Segev DL; Dharnidharka VR; Naik AS; Lam NN; Ouseph R; Kasiske BL; Durand CM; Lentine KL
Am J Transplant; 2018 Oct; 18(10):2473-2482. PubMed ID: 29701909
[TBL] [Abstract][Full Text] [Related]
9. Improving Liver Transplant Outcomes for Hepatitis C Virus Hepatocellular Carcinoma in the Direct-Acting Antiviral Therapy Era.
Okumura K; Sogawa H; Samson D; Butler J; Veillette G; John D; Diflo T; Bodin R; Wolf DC; Latifi R; Nishida S
Transplant Proc; 2022 Sep; 54(7):1834-1838. PubMed ID: 35933231
[TBL] [Abstract][Full Text] [Related]
10. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
[TBL] [Abstract][Full Text] [Related]
11. Decreasing frequency and improved outcomes of hepatitis C-related liver transplantation in the era of direct-acting antivirals - a retrospective cohort study.
Arora SS; Axley P; Ahmed Z; Satapathy SK; Wong R; Kuo YF; Singal AK
Transpl Int; 2019 Aug; 32(8):854-864. PubMed ID: 30866110
[TBL] [Abstract][Full Text] [Related]
12. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals.
Young K; Liu B; Bhuket T; Wong RJ
J Clin Exp Hepatol; 2020; 10(6):581-589. PubMed ID: 33311895
[TBL] [Abstract][Full Text] [Related]
13. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras.
Jacob JS; Shaikh A; Goli K; Rich NE; Benhammou JN; Ahmed A; Kim D; Rana A; Goss JA; Naggie S; Lee TH; Kanwal F; Cholankeril G
Clin Infect Dis; 2023 Feb; 76(4):592-599. PubMed ID: 36221143
[TBL] [Abstract][Full Text] [Related]
14. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
Cannon RM; Locke JE; Orandi BJ; Anderson DJ; Davis EG; Mackelaite L; Dave H; Eng M; Jones CM
Transplantation; 2020 Jun; 104(6):1215-1228. PubMed ID: 31517783
[TBL] [Abstract][Full Text] [Related]
15. In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent.
Bittermann T; Reddy KR
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2389-2397.e2. PubMed ID: 32971230
[TBL] [Abstract][Full Text] [Related]
16. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience.
Alkadi MM; Abuhelaiqa EA; Elshirbeny MF; Hamdi AF; Fituri OM; Asim M; Alkaabi SR; Derbala MF; Jarman ME; Ashour AM; Nauman A; Al Maslamani YK; Butt AA; Al-Malki HA
Immun Inflamm Dis; 2021 Mar; 9(1):246-254. PubMed ID: 33264509
[TBL] [Abstract][Full Text] [Related]
17. "Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era.
Cotter TG; Wang J; Lieber SR; Odenwald MA; Rich NE; Marrero JA; Singal AG; Mitchell MC; Aronsohn A; Charlton M; Fung J
Transplant Direct; 2021 Jul; 7(7):e707. PubMed ID: 34124343
[TBL] [Abstract][Full Text] [Related]
18. Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era.
Bowring MG; Kucirka LM; Massie AB; Luo X; Cameron A; Sulkowski M; Rakestraw K; Gurakar A; Kuo I; Segev DL; Durand CM
Am J Transplant; 2017 Feb; 17(2):519-527. PubMed ID: 27456927
[TBL] [Abstract][Full Text] [Related]
19. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
[TBL] [Abstract][Full Text] [Related]
20. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
Young K; Liu B; Bhuket T; Gish RG; Wong RJ
J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]